Despite the advance of immunotherapy, only a small subset of patients gains long-term
survival benefit. This fact represents a compelling rationale to develop immuno-PET imaging …

Immune checkpoint inhibitors (ICIs) are now commonly used to treat patients with metastatic
malignant melanoma. Although concerns have been raised that the inflammatory response …

Cancer immunotherapy focuses on the development of agents that can activate the immune
system to recognize and kill tumour cells. It encompasses different strategies, the first of …

Purpose: We explored imaging and blood bio-markers for survival prediction in a cohort of
patients with metastatic melanoma treated with immune checkpoint inhibition. Materials and …

Abstract Purpose Immune checkpoint inhibitors (ICIs) are widely used in metastatic
melanoma and dramatically alter the treatment of these patients. Given the high cost and …

Combination anti–cytotoxic T lymphocyte antigen 4 (CTLA-4) and anti–programmed cell
death protein 1 (PD-1) therapy promotes antitumor immunity and provides superior benefit to …

Although the role of the immune system in modulating the behavior of cancers has long
been suspected and the focus of prior therapeutic interventions, the recent development of …

Programmed cell death ligand 1 (PD-L1) is part of an immune checkpoint system that is
essential for preventing autoimmunity and cancer. Recent approaches in immunotherapy …

In line with the ongoing phase I trial (NCT03784625) dedicated to melanoma targeted
radionuclide therapy (TRT), we explore the interplay between immune system and the …

Purpose Immune checkpoint inhibitors can induce a T cell–mediated anti-tumor immune
response in patients with melanoma. Visualizing T cell activity using positron emission …